Loading…
Precigen, Inc. is projected to rise to $5.54 by 2027, a +26% move from its current price of $4.40. PGEN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.25 | $4.40 | $4.56 | +0.06% |
| May 30 | $4.19 | $4.41 | $4.63 | +0.12% |
| May 31 | $4.15 | $4.41 | $4.68 | +0.19% |
| Jun 1 | $4.12 | $4.41 | $4.73 | +0.25% |
| Jun 2 | $4.08 | $4.41 | $4.77 | +0.31% |
| Jun 3 | $4.06 | $4.42 | $4.81 | +0.37% |
| Jun 4 | $4.03 | $4.42 | $4.84 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.03 | $4.42 | $4.84 | +0.43% |
| Week 2 | $3.90 | $4.44 | $5.05 | +0.87% |
| Week 3 | $3.80 | $4.46 | $5.22 | +1.31% |
| Week 4 | $3.73 | $4.48 | $5.38 | +1.74% |
| Week 5 | $3.66 | $4.50 | $5.52 | +2.19% |
| Week 6 | $3.61 | $4.52 | $5.65 | +2.63% |
| Week 7 | $3.56 | $4.54 | $5.78 | +3.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms include AdenoVerse, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
The company is developing programs based on UltraCAR-T and AdenoVerse platforms, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc.
in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Precigen, Inc. (PGEN) is a healthcare company currently priced at $4.24 with a market cap of $1.51B. It ranks 2224 by market cap, reflecting its position in the broad market. The current price and market footprint sit within a context of a multi-year forecast that envisions a rising average price over time, indicating potential upside from the present level.
A major floor 29.5% below — a decisive break under it would weaken the trend.
The nearest floor, 11.4% below — buyers have tended to step in here.
The nearest ceiling, 4.5% above — a clean break opens room to run.
A major ceiling 18.4% above — clearing it would confirm fresh momentum.
Key PGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.29 | Buy | $4.30 | Buy |
| MA 10 | $4.28 | Buy | $4.27 | Buy |
| MA 20 | $4.23 | Buy | $4.22 | Buy |
| MA 50 | $3.98 | Buy | $4.10 | Buy |
| MA 100 | $4.12 | Buy | $4.01 | Buy |
| MA 200 | $3.96 | Buy | $3.68 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.01 | Neutral |
| Stoch RSI (14) | 53.65 | Neutral |
| CCI (20) | 103.29 | Buy |
| Williams %R (14) | -37.74 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 4.51 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 62.26 | Neutral |
| TRIX (15) | 0.30 | Buy |
| Awesome (5,34) | 0.13 | Buy |
| Ultimate (7,14,28) | 50.27 | Neutral |
| Momentum (10) | 0.32 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 4.29 | Buy |
| ADX (14) | 10.07 | Neutral |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is described as BULLISH. RSI14 is 50, and moving averages show SMA50 at $3.95 and SMA200 at $3.93, with a defined daily trading framework of support at $3.90 and resistance at $4.60. The 30-day range spans from $3.34 to $5.38, underscoring measurable volatility in the near term with annualized volatility at 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.10 | $4.40 | $6.24 | 0% | Neutral | |
| $4.28 | $5.54 | $7.66 | +26% | Bullish | |
| $4.81 | $6.46 | $9.33 | +47% | Bullish | |
| $4.42 | $6.11 | $9.14 | +39% | Bullish | |
| $4.93 | $7.00 | $10.77 | +59% | Bullish | |
| $6.21 | $9.03 | $14.25 | +105% | Bullish | |
| $7.05 | $10.51 | $16.95 | +139% | Bullish | |
| $8.04 | $12.24 | $20.15 | +178% | Bullish | |
| $8.30 | $12.90 | $21.64 | +193% | Bullish | |
| $8.29 | $13.15 | $22.44 | +199% | Bullish | |
| $13.21 | $22.99 | $42.18 | +422% | Bullish | |
| $18.23 | $37.44 | $76.23 | +751% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.10 | $4.40 | $5.18 | +0.00% |
| June 2026 | $3.79 | $4.48 | $5.44 | +1.80% |
| July 2026 | $3.90 | $4.66 | $5.75 | +3.92% |
| August 2026 | $3.82 | $4.60 | $5.75 | -1.21% |
| September 2026 | $3.72 | $4.51 | $5.69 | -2.00% |
| October 2026 | $3.83 | $4.67 | $5.96 | +3.63% |
| November 2026 | $3.93 | $4.83 | $6.21 | +3.39% |
| December 2026 | $3.90 | $4.81 | $6.24 | -0.29% |
Click any year to see its month-by-month PGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Precigen, Inc.'s 2026 outlook centres on $4.40, within a $3.10 to $6.24 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, PGEN could reach as high as $7.66, with a base case around $5.54 and support toward $4.28 — roughly +26% from $4.40. Momentum favours further upside here.
Expect PGEN to range from $4.81 to $9.33 through 2028. The $6.46 average target implies a +47% move from current prices. That is up +17% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The PGEN price prediction for 2029 points to an average of $6.11 (low $4.42, high $9.14) — a potential gain of +39% on today's $4.40. Momentum favours further upside here.
In 2030, PGEN is projected to trade between $4.93 and $10.77, averaging $7.00 — a potential gain of +59% from today's $4.40. That is up +14% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Precigen, Inc.'s 2031 outlook centres on $9.03, within a $6.21 to $14.25 range. That is up +29% on the projected 2030 average. That marks a +105% change versus current levels. Momentum favours further upside here.
By 2032, PGEN could reach as high as $16.95, with a base case around $10.51 and support toward $7.05 — roughly +139% from $4.40. Buyers look set to stay in control over this stretch.
Expect PGEN to range from $8.04 to $20.15 through 2033. The $12.24 average target implies a +178% move from current prices. That is up +16% on the projected 2032 average. Momentum favours further upside here.
The PGEN price prediction for 2034 points to an average of $12.90 (low $8.30, high $21.64) — a potential gain of +193% on today's $4.40. Buyers look set to stay in control over this stretch.
In 2035, PGEN is projected to trade between $8.29 and $22.44, averaging $13.15 — a potential gain of +199% from today's $4.40. That is up +2% on the projected 2034 average. Momentum favours further upside here.
Precigen, Inc.'s 2040 outlook centres on $22.99, within a $13.21 to $42.18 range. That is up +75% on the projected 2035 average. That marks a +422% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, PGEN could reach as high as $76.23, with a base case around $37.44 and support toward $18.23 — roughly +751% from $4.40. Momentum favours further upside here.
Investing $1,000 in PGEN today (≈ 227.272727 PGEN) could be worth
$8,509.53
+$7,509.53 (+751%) by 2050 · US Dollar
Based on the average projected PGEN price of $37.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PGENwould be worth at today's price.
$1,000 invested in PGEN on May 27, 2025 (≈ 709.219875 PGEN) would be worth
$3,120.57
+$2,120.57 (+212.1%) today · 3.12× · US Dollar
Based on a PGEN entry price of $1.41 vs. today's $4.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.27 | $1,030.44 | +3.0% |
| 1 month ago | $3.96 | $1,111.11 | +11.1% |
| 3 months ago | $3.81 | $1,154.86 | +15.5% |
| 6 months ago | $3.83 | $1,148.83 | +14.9% |
| 1 year ago | $1.41 | $3,120.57 | +212.1% |
| All time (5.0y) ago | $6.62 | $664.65 | -33.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PGEN forecast.
Our base-case forecast reaches $8.80 around 2031.
Implied market cap at $8.80: $3.14B
The multi-year forecast points to a bullish trajectory with steady price advancement across the decades. In 2026 the min is $3.10, the avg is $4.24, and the max is $6.03 with an ROI of 0 and sentiment Neutral. By 2027 the avg rises to $5.31 (max $7.40; min $4.08) with an ROI of 25.3 and sentiment Bullish, and the trend continues through 2030 with an avg of $6.51 and a max of $10.11, ROI 53.4, sentiment Bullish.
The path extends to 2040, where the avg is $20.42 and the max $38.03, ROI 381.7, sentiment Bullish, and culminates in 2050 with an avg of $32.61 and a max of $67.55, ROI 669.1, sentiment Bullish. These are estimates, not guarantees, and reflect upside potential alongside inherent investment uncertainties.
Tap a question to reveal the answer.
2030 min $4.54, avg $6.51, max $10.11; ROI 53.4; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages and positive ROI values, including 2027 avg $5.31, ROI 25.3; 2031 avg $8.31, ROI 96; 2040 avg $20.42, ROI 381.7; 2050 avg $32.61, ROI 669.1. These are estimates, not guarantees.
2035 max $20.43, avg $11.81; 2030 avg $6.51; 2040 avg $20.42 with max $38.03. The forecast therefore indicates the possibility of around $20.43 by 2035 in the max scenario.
Current price $4.24; Market cap $1.51B.
2050 max $67.55; 2050 avg $32.61; ROI 669.1; sentiment BULLISH.
Precigen, Inc. Community Discussion
0Share your Precigen, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.